Fundraising FoxNewomics
Berkeley, US · Delaware corporation · 3 known investors
Find your way into Newomics
Each arrow is one introduction. Sign up to fill in the first one.
Ask Philippe Goix to introduce you to Pan Mao
You →Philippe · together at Genotixbio →Pan
Sign up to find every way you can get introduced to Newomics
- Your email: who you already know at Newomics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Newomics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Newomics develops the UniESI system, a multiomics front-end platform using its M3 emitter and MEA chip "multispray" technologies for microflow and nanoflow LC-MS. The system serves as a dual nano/micro ion source for mass spectrometers, targeting applications in native MS, proteomics, metabolomics, and single-cell omics.
Founders & leadership
Board
Investors · 3
How we know: the VCSheet dataset · Not right? Tell us
How we know: funding news · Not right? Tell us
How we know: funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$3.9M disclosed across 1 round · 2020
▶$3.9MraisedOct 2020 · 10 investors · BiotechnologyRule 506(b)
- Pan MaoDirector
- Patrick ScannonDirector
- Ted HouDirector
- Daojing WangExecutive Officer, Director
- Offering amount
- $7.9M
- Amount sold
- $3.9M
- First sale
- Oct 2020
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 3
Companies working in the same space as Newomics.
Non-dilutive funding · 13 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2022 | $1.7M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $3M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2015 | $1.5M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $700K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $683.2K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $600K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2014 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2013 | $300K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2013 | $225K |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2012 | $250K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Newomics do?
- Newomics develops the UniESI system, a multiomics front-end platform using its M3 emitter and MEA chip "multispray" technologies for microflow and nanoflow LC-MS. The system serves as a dual nano/micro ion source for mass spectrometers, targeting applications in native MS, proteomics, metabolomics, and single-cell omics.
- Who founded Newomics?
- Newomics was founded by Pan Mao, Daojing Wang.
- Who are Newomics's investors?
- Newomics's investors include Berkeley Catalyst, LDV Partners, MSA Capital.
- How much funding has Newomics raised?
- Newomics has disclosed $3.9M raised across 1 round.
- Where is Newomics headquartered?
- Newomics is headquartered in Berkeley, US.